FDA adds to recall warning over Zilver PTX stent (Cook Medical) for PAD
The FDA has added a serious warning to Cook Medical's recall of its Zilver PTX paclitaxel eluting stent for PAD. The recall was ordered on April 18 2013, soon after the device received FDA approval. Cook Medical received a small number of complaints that the delivery system of the device had separated at the tip of the inner catheter. Potential adverse events that may occur in cases where the inner deliver catheter breakage occurs include possible surgery to remove the catheter tip. However the upgraded Class 1 recall warning states that problems with the Zilver's delivery catheter could lead to thrombosis, amputation or death.
Related news and insights
Genentech/Roche announced that the FDA has approved Susvimo (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of people with wet, or neovascular, age-related macular degeneration (AMD) who have previously responded to at least two anti-vascular endothelial growth factor (VEGF) injections.
Oncopeptides announced that the company has decided to withdraw Pepaxto (INN melphalan flufenamide) from the market in the US, following the phase III OCEAN study, which showed an overall survival in the ITT population with a HR of 1.104. The decision has been made after interactions and dialogue with the FDA. Pepaxto was granted accelerated approval on February 26th 2021.
Johnson & Johnson announced the FDA has issued Emergency Use Authorization (EUA) for a booster dose of the Johnson & Johnson COVID-19 vaccine for adults aged 18 and older at least two months following primary vaccination with single-shot Johnson & Johnson COVID-19 vaccine; and for eligible individuals who received a different authorized or approved COVID-19 vaccine.